HighGravityDataGilead Sciences — Oct 30, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000882095-25-000044
Showing in the filing
Non-GAAP projected operating income
“$13,100 - $13,400”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 20
Product sales for FY2025
“$ 28,400 $ 28,700”
Product sales
“$ 28,400”
Product sales excluding Veklury for FY2025
“$ 27,400 $ 27,700”
Product sales excluding Veklury
“$ 27,400”
Veklury for FY2025
“$ 1,000 $ 1,000”
Veklury
“$ 1,000”
Diluted EPS for FY2025
“$ 6.65 $ 6.85”
Diluted EPS
“$ 6.65”
Non-GAAP diluted EPS for FY2025
“$ 8.05 $ 8.25”
Non-GAAP diluted EPS
“$ 8.05”
Quarterly dividend declared for Q4 FY2025
“$0.79”
Quarterly dividend of common stock for Q4 FY2025
“$0.79 per share”
Planned investment in the U.S. for FY2030
“$32 billion”
Planned U.S. manufacturing and R&D investment for FY2030
“$32 billion”
GAAP projected product gross margin for FY2025
“~ 78.0%”
Non-GAAP projected product gross margin for FY2025
“~ 86.0%”
GAAP projected operating income for FY2025
“$10,300 - $10,600”
Non-GAAP projected operating income for FY2025
“$13,100 - $13,400”
GAAP projected effective tax rate for FY2025
“~ 16%”
Non-GAAP projected effective tax rate for FY2025
“~ 19%”
Exhibit 99.1 · the passage around this item
… earlier in the release
RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL-YEAR GUIDANCE (1) (unaudited) (in millions, except percentages and per share amounts) Provided February 11, 2025 Updated April 24, 2025 Updated August 7, 2025 Updated October 30, 2025 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin 77.0% - 78.0% 77.0% - 78.0% ~ 78.0% ~ 78.0% Acquisition-related expenses ~ 8.0% ~ 8.0% ~ 8.0% ~ 8.0% Non-GAAP projected product gross margin 85.0% - 86.0% 85.0% - 86.0% ~ 86.0% ~ 86.0% Projected operating income GAAP to non-GAAP reconciliation: GAAP projected operating income $10,200 - $10,700 $10,200 - $10,700 $10,300 - $10,700 $10,300 - $10,600 Acquisition-related, IPR&D impairment and restructuring expenses ~ 2,500 ~ 2,500 ~ 2,700 ~ 2,800 Non-GAAP projected operating income $12,700 - $13,200 $12,700 - $13,200 $13,000 - $13,400 $13,100 - $13,400 Projected effective tax rate GAAP to non-GAAP reconciliation: GAAP projected effective tax rate (2) ~ 20% ~ 21% ~ 21% ~ 16% Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments (2) (~ 1%) (~ 2%) (~ 2%) ~ 3% Non-GAAP projected effective tax rate ~ 19% ~ 19% ~ 19% ~ 19% Projected diluted EPS GAAP to non-GAAP reconciliation: GAAP projected diluted EPS $5.95 - $6.35 $5.65 - $6.05 $5.85 - $6.15 $6.65 - $6.85 Acquisition-related, IPR&D impairment and restructuring expenses, fair value adjustments of equity securities and discrete and related tax adjustments (2) ~ 1.75 ~ 2.05 ~ 2.10 ~ 1.40 Non-GAAP projected diluted EPS $7.70 - $8.10 $7.70 - $8.10 $7.95 - $8.25 $8.05 - $8.25 ________________________________ (1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.